Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer

Journal of the College of Physicians and Surgeons Pakistan

Volumn 20, Issue 11, 2010, Pages 748-752

  Akhtar, Muhammad Sohail ^a   Kousar, Farzana ^b   Masood, Misbah ^c   Fatimi, Shahab ^a   Kokab, ^a  

^a Bahawalpur Institute of Nuclear Medicine and Oncology BINO   (Pakistan)

^b Centre for Nuclear Medicine (CENUM)   (Pakistan)

^c Institute of Nuclear Medicine and Oncology INMOL   (Pakistan)

Author keywords

Breast cancer; Carboplatin; Chemotherapy; FAC; Neoadjuvant; Paclitaxil

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 78649422507     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Beahrs OH, Henderson DE. Hutter RV, Myers MH, editors. Manual for staging of cancer. Philadelphia: JB Lippincot; 1993.
2. Carlson RW, Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, et al. Treatment of breast cancer in countries with limited resources. Breast J 2003; 9:S67-74.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
4. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumour removal in mice. Cancer Res 1989; 49:1996-2001.
5. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of pre-operative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-93.
6. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. 1998 Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-85.
7. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19:278-85.
8. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10:1014-24.
9. Mincey BA, Perez EA. Concise review for clinicians: advances in screening, diagnosis and treatment of breast cancer. Mayo Clin Proceedings 2004; 79:810-6.
10. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44:355-61.
11. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14:31-6.
12. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-72.
13. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 1998; 95:3896-901.
14. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-201.
15. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an inter-group trial (E1193). J Clin Oncol 2003; 21:588-92.
16. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992; 339:71-85.
17. Comment in: Lancet 1992; 339(8790):423-4.
18. Henderson IC, Berry D, Demetri G. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998; 17:101a.
19. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88:124-31.
20. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Briasoulis E, et al. Paclitaxel by 3-h infusion and carboplatin in anthracyclineresistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997; 33:1893-5.
21. Fitch RA, Suman VJ, Mailliard JA. N9932: phase II co-operative group trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy for metastatic breast cancer (MBA). Proc Am Soc Clin Oncol 2003; 22:23.
22. Green MC, Buzdar AU, Smith T. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a.